Platelet Disease

Angelol D is an angelol-type coumarin found in the roots of Angelica pubescens f. biserrata. Angelol D inhibits ADP-induced human platelet aggregation, with a IC₅₀ of 0.30 mM against ADP-induced human platelet aggregation. Angelol D can be used for the research of platelet-related diseases.

Furosemide AG (Furosemide acyl-β-D-glucuronide) is an acyl-β-D-glucuronide metabolite of Furosemide (HY-B0135). Furosemide AG can be used in the research of neutropenia and thrombocytopenia.

CFM 1571 is a soluble guanylyl cyclase (sGC) activator with an IC₅₀ of ~5.5 μM. CFM 1571 activates sGC in a NO-independent manner and exerts a synergistic effect with NO. CFM 1571 inhibits platelet aggregation.

RWJ-58259 is a selective PAR-1 inhibitor with an IC₅₀ value of 0.15 μM. RWJ-58259 binds selectively to PAR-1, blocks the binding of tethered ligands, interferes with calcium mobilization and PAR-1-related cellular functions, and exhibits no PAR-1 agonist activity or thrombin proteolytic inhibitory activity. RWJ-58259 inhibits thrombin-induced platelet aggregation, calcium signaling and vascular smooth muscle cell proliferation, reduces neointimal thickness and arterial stenosis, and alleviates vascular occlusion and platelet deposition. RWJ-58259 can be used in the research of thrombotic diseases and vascular injury associated with acute coronary intervention.

KC-11404 is an orally active antihistamine and 5-lipoxygenase inhibitor, with an IC₅₀ of 0.9 μM against guinea pig 5-lipoxygenase. KC-11404 inhibits histamine-induced contraction of isolated guinea pig ileum with an IC₅₀ of 0.26 μM. KC-11404 inhibits PAF-induced rabbit platelet aggregation with an IC₅₀ of 2.0 μM. It inhibits the histamine phase of antigen-induced bronchoconstriction and PAF-induced bronchoconstriction in guinea pigs. KC-11404 can be used for the research of asthma.

U 84569 is a potent low-Km cAMP-dependent Phosphodiesterase inhibitor, with an IC₅₀ value of 300 nM in platelet cytosol. By inhibiting phosphodiesterase and elevating cAMP levels, U 84569 indirectly blocks receptor-mediated Phospholipase C activation, thereby inhibiting platelet aggregation.

RX-RA-69 is an orally active platelet phosphodiesterase (PDE) inhibitor with a IC₅₀ of 1 nM. RX-RA-69 elevates cAMP levels in platelets, exerts anti-aggregatory effects, and inhibits the formation of coronary platelet thrombi. RX-RA-69 exhibits anti-metastatic activity in a mouse Lewis lung cancer model. RX-RA-69 can be used in research related to coronary platelet thrombi and Lewis lung cancer.

LN5972 is a selective ACKR3 agonist with an EC₅₀ of 3.40 μM, showing higher selectivity for ACKR3 over CXCR4. LN5972 induces β-arrestin recruitment to ACKR3/CXCR7. LN5972 reduces the surface expression of P-selectin. LN5972 is applicable to studies related to platelet-mediated thrombosis.

DT-678 is an orally active antiplatelet and antithrombotic inhibitor. DT-678 is a conjugate formed by linking the active metabolite of Clopidogrel (HY-15283) with 3-nitropyridine-2-thiol via a mixed disulfide bond. DT-678 does not rely on CYP2C19 for activation, and directly releases active substances via thiol exchange reactions in vivo, exhibiting superior efficacy over Clopidogrel. DT-678 can be used in research related to acute coronary syndrome and thrombosis.

5,7-Dihydroxytryptamine (5,7-DHP) is an autofluorescent (λ_ex≈365 nm), selective neurotoxin and a transport substrate for MAO-A and 5-HT. 5,7-Dihydroxytryptamine can specifically target and damage central and peripheral 5-HTergic neurons, while affecting 5-HT-related pathways and neurotransmitter balance. 5,7-Dihydroxytryptamine can be used to establish 5-HTergic neuron injury models for studies on neural development, neurodegenerative diseases, as well as mechanisms related to platelet function and retinal neurons.

Desmodilactone is a P2Y1R allosteric antagonist. Desmodilactone can be used for the research of thrombosis.

Tribuluside A is a steroidal saponin present in Tribulus terrestris. Tribuluside A inhibits U-46619 (HY-108566)-induced platelet aggregation. Tribuluside A can be used for the research of platelet aggregation-related processes.

1-Palmitoyl-sn-glycerol 3-phosphate-d₉ (1-P-GPA-d₉) is the d₉ labeled 1-Palmitoyl-sn-glycerol 3-phosphate (HY-126967A). 1-Palmitoyl-sn-glycerol 3-phosphate (1-P-GPA) is a phospholipid and lipid membrane precursor. 1-Palmitoyl-sn-glycerol 3-phosphate integrates into POPC liposomes, causing significant changes in membrane curvature. 1-Palmitoyl-sn-glycerol 3-phosphate induces platelet aggregation, but its activity is 30-fold lower than that of 1-hexadecyl-sn-glyceryl-3-phosphate.

YM-254891 is a YM-254890 (HY-111557) analogue and Gαq/11 inhibitor. YM-254891 can be isolated from the fermentation broth of Chromobacterium sp. QS3666. YM-254891 inhibits ADP-induced platelet aggregation.

CID-103 (TSK011010) is an anti-CD38 antibody that recognizes a unique epitope on CD38. CID-103 can be used in research on immune thrombocytopenia.

Gy-CATH is an anionic antimicrobial peptide. Gy-CATH activates MAPK and NF-κB signaling pathways (elevated levels of phospho-ERK, -p38, -JNK, -p65, and -IκBα). Gy-CATH upregulates the expression levels of three physiological anticoagulant pathways. Gy-CATH inhibits ADP-, Collagen-, and PMA-induced platelet aggregation. Gy-CATH has no direct antimicrobial activity, but shows significant preventive abilities against mice infected with Staphylococcus aureus, Escherichia coli, and Methicillin (HY-121544)-resistant Staphylococcus aureus. Gy-CATH exhibits potent immunomodulatory activity, enhancing macrophage-and neutrophil-mediated bactericidal functions. Gy-CATH significantly reduces the extent of pulmonary fibrin deposition and prevents thrombosis in mice.

Ac-RGDS-NH2, a tetrapeptide, is an integrin antagonist. Ac-RGDS-NH2 competitively binds to the GPIIb/IIIa receptor (K_i = 4.2 μM), inhibiting the binding of fibrinogen to platelets and thereby effectively suppressing platelet aggregation. Ac-RGDS-NH2 can be used for research on thrombosis.

D-RGDW is an Arg-Gly-Asp (RGD) containing peptide. D-RGDW inhibits αIIbβ3 mediated platelet aggregation.

Itazigrel (U-53059) is an orally active antiplatelet agent. Itazigrel inhibits cyclooxygenase activity. Itazigrel inhibits platelet aggregation.

Sergolexole maleate is a potent 5-HT₂ receptor antagonist. Sergolexole maleate antagonizes serotonin-amplified platelet aggregation.